Eight Roads Ventures, a venture capital firm, led a $38m Series A+ round in Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer, with participation from F-Prime Capital, ABio-X, Delta Capital, and Trinity. “We are thrilled to have Eight Roads and our investors supporting our mission to bring innovative treatments to patients. Over the last two years, we have made significant progress advancing our emerging therapeutic pipeline that implements our proprietary and differentiated technology platform. This new round of funding from our investors will enable Adcentrx to quickly advance our safer and more efficacious conjugate therapies for patients in need. This year will be pivotal for Adcentrx, when we transition from the discovery stage into a clinical stage company," Hui Li, Adcentrx Founder and CEO.